NeuroPace (NPCE) CEO receives new RSU and stock option awards

Rhea-AI Filing Summary

NeuroPace Inc CEO Joel Becker reported equity awards consisting of restricted stock units and stock options. He received 45,880 RSU-based shares of common stock, bringing his common stock holdings to 142,817 shares. He was also granted options on 122,190 shares at an exercise price of $15.36, expiring on May 14, 2036.

The RSUs vest 25% on May 15, 2027, with the remainder in twelve equal quarterly installments. The stock options vest 25% on May 15, 2027, with the remaining shares vesting in thirty-six equal monthly installments thereafter.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Becker Joel

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	122,190	$0.00	--
Grant/Award	Common Stock	45,880	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 122,190 shares (Direct, null); Common Stock — 142,817 shares (Direct, null)

Footnotes (1)

1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. 25% of the shares subject to the option vest on May 15, 2027. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.

Key Figures

RSU grant size: 45,880 shares Common shares held after grant: 142,817 shares Stock options granted: 122,190 options +4 more

7 metrics

RSU grant size 45,880 shares Restricted stock units representing common stock granted to CEO

Common shares held after grant 142,817 shares Direct common stock ownership following RSU grant

Stock options granted 122,190 options Options on common stock granted to CEO

Option exercise price $15.36 per share Conversion or exercise price for newly granted stock options

Option expiration date May 14, 2036 Expiration of stock options on 122,190 shares

Initial RSU vesting date May 15, 2027 25% of RSUs vest on this date

Initial option vesting date May 15, 2027 25% of options vest on this date

Key Terms

restricted stock unit ("RSU"), contingent right, Stock Option (Right to Buy), vest, +1 more

5 terms

restricted stock unit ("RSU") financial

"Each share is represented by a restricted stock unit ("RSU")."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest financial

"25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: "15.3600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Becker Joel

(Last) (First) (Middle)

C/O NEUROPACE INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW CALIFORNIA 94043

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		A		45,880(1)	A	$0	142,817	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.36	05/15/2026		A		122,190		(2)	05/14/2036	Common Stock	122,190	$0	122,190	D

Explanation of Responses:

1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.

2. 25% of the shares subject to the option vest on May 15, 2027. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did NeuroPace (NPCE) CEO Joel Becker report in this Form 4?

Joel Becker reported equity awards of RSUs and stock options. He received 45,880 RSU-based common shares and options on 122,190 shares, all as grants with no cash purchase, increasing his reported direct equity exposure in NeuroPace.

How many NeuroPace (NPCE) shares does Joel Becker hold after this grant?

After the grant, Joel Becker holds 142,817 common shares directly. In addition, he was granted stock options covering 122,190 underlying common shares, giving him both outright ownership and the right to buy more shares at a set exercise price.

What are the key terms of Joel Becker’s NeuroPace RSU grant?

The RSU grant covers 45,880 common shares. Each restricted stock unit represents one share upon settlement. Twenty-five percent vest on May 15, 2027, and the remaining units vest in twelve equal quarterly installments after that initial vesting date.

What are the vesting terms of Joel Becker’s NeuroPace stock options?

The option grant covers 122,190 shares at a $15.36 exercise price. Twenty-five percent of these options vest on May 15, 2027. The remaining options vest in thirty-six equal consecutive monthly installments following that date, subject to continued vesting conditions.

When do Joel Becker’s newly granted NeuroPace stock options expire?

The stock options granted to Joel Becker expire on May 14, 2036. They are exercisable for 122,190 underlying common shares at an exercise price of $15.36, following the specified vesting schedule beginning on May 15, 2027.

Is Joel Becker’s Form 4 transaction a market purchase or a compensation grant?

The transactions are compensation-related grants, not open-market purchases. Both the 45,880 RSU-based shares and the 122,190 stock options were reported with a zero purchase price and classified as grant or award acquisitions under transaction code A.